Completed PHASE3 INTERVENTIONAL 2-arm NCT02095990

Efficacy and Safety of a 4% Hydroquinone Cream for the Treatment of Melasma

Efficacy and Safety of a 4% Hydroquinone Cream (Melanoderm 4%) for the Treatment of Melasma: a Randomized Controlled Split-face Study

Sponsor: Mesoestetic Pharma Group S.L.

Conditions Facial Melasma

Interventions Hydroquinone Placebo

Updated 6 times since 2017 Last updated: Sep 27, 2019 Started: Mar 31, 2014 Primary completion: Aug 31, 2014 Completion: Aug 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Facial Melasma, this trial is completed. The trial is conducted by Mesoestetic Pharma Group S.L. and has accumulated 6 data snapshots since 2014. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Oct 2019 — Jan 2021 [monthly]

Completed PHASE3
Jun 2018 — Oct 2019 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Mar 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Mesoestetic Pharma Group S.L.

Data source: Mesoestetic Pharma Group S.L.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Barcelona, Spain